28155918|t|Surface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action
28155918|a|The alarming increase of pathogenic bacteria that are resistant to multiple antibiotics is now recognized as a major health issue fuelling demand for new drugs. Bacterial resistance is often caused by molecular changes at the bacterial surface, which alter the nature of specific drug-target interactions. Here, we identify a novel mechanism by which drug-target interactions in resistant bacteria can be enhanced. We examined the surface forces generated by four antibiotics; vancomycin, ristomycin, chloroeremomycin and oritavancin against drug-susceptible and drug-resistant targets on a cantilever and demonstrated significant differences in mechanical response when drug-resistant targets are challenged with different antibiotics although no significant differences were observed when using susceptible targets. Remarkably, the binding affinity for oritavancin against drug-resistant targets (70 nM) was found to be 11,000 times stronger than for vancomycin (800 Î¼M), a powerful antibiotic used as the last resort treatment for streptococcal and staphylococcal bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Using an exactly solvable model, which takes into account the solvent and membrane effects, we demonstrate that drug-target interactions are strengthened by pronounced polyvalent interactions catalyzed by the surface itself. These findings further enhance our understanding of antibiotic mode of action and will enable development of more effective therapies.
28155918	0	7	Surface	T082	UMLS:C0205148
28155918	29	50	interactions of drugs	T038	UMLS:C0687133
28155918	81	91	antibiotic	T103	UMLS:C0003232
28155918	153	186	resistant to multiple antibiotics	T038	UMLS:C0860044
28155918	238	244	demand	T058	UMLS:C0441516
28155918	253	258	drugs	T103	UMLS:C1254351
28155918	260	280	Bacterial resistance	T038	UMLS:C0151521
28155918	300	317	molecular changes	T033	UMLS:C0262496
28155918	325	342	bacterial surface	T033	UMLS:C0201029
28155918	379	403	drug-target interactions	T038	UMLS:C0687133
28155918	450	474	drug-target interactions	T038	UMLS:C0687133
28155918	478	496	resistant bacteria	T007	UMLS:C1444090
28155918	530	537	surface	T082	UMLS:C0205148
28155918	530	537	surface	T082	UMLS:C0205148
28155918	563	574	antibiotics	T103	UMLS:C0003232
28155918	576	586	vancomycin	T103	UMLS:C0042313
28155918	588	598	ristomycin	T103	UMLS:C0917879
28155918	600	616	chloroeremomycin	T103	UMLS:C0674648
28155918	621	632	oritavancin	T103	UMLS:C1144403
28155918	662	684	drug-resistant targets	T007	UMLS:C4076168
28155918	770	792	drug-resistant targets	T007	UMLS:C4076168
28155918	823	834	antibiotics	T103	UMLS:C0003232
28155918	933	949	binding affinity	T038	UMLS:C0678749
28155918	954	965	oritavancin	T103	UMLS:C1144403
28155918	974	996	drug-resistant targets	T007	UMLS:C4076168
28155918	1052	1062	vancomycin	T103	UMLS:C0042313
28155918	1084	1094	antibiotic	T103	UMLS:C0003232
28155918	1112	1128	resort treatment	T058	UMLS:C0087111
28155918	1133	1146	streptococcal	T007	UMLS:C0038402
28155918	1151	1174	staphylococcal bacteria	T007	UMLS:C0038170
28155918	1185	1228	methicillin-resistant Staphylococcus aureus	T007	UMLS:C1265292
28155918	1230	1234	MRSA	T007	UMLS:C1265292
28155918	1246	1268	exactly solvable model	T170	UMLS:C0282574
28155918	1299	1306	solvent	T103	UMLS:C0037638
28155918	1311	1319	membrane	T017	UMLS:C0596901
28155918	1349	1373	drug-target interactions	T038	UMLS:C0687133
28155918	1394	1428	pronounced polyvalent interactions	T038	UMLS:C0687133
28155918	1446	1453	surface	T082	UMLS:C0205148
28155918	1497	1510	understanding	T038	UMLS:C0162340
28155918	1586	1595	therapies	T058	UMLS:C0087111